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Angiotensin converting enzyme inhibition and calcium channel block-
ade in incipient diabetic nephropathy. Small increases in blood pressure
are a feature of incipient diabetic nephropathy, and mean blood
pressure often correlates with the degree of albuminuria in such
patients. Antihypertensive therapy with angiotensin converting enzyme
inhibitors (CEI) or calcium channel blockers (CCB) has been assessed
in several studies to determine if either form of treatment modifies
incipient diabetic nephropathy and its evolution to established nephrop-
athy. The acute renal hemodynamic effects of CET differ from those of
CCB under certain circumstances. In incipient diabetic nephropathy,
therapy with CEI but not CCB tends to reduce filtration fraction,
especially in hyperfiltering patients. In hypertensive patients with
incipient diabetic nephropathy, both treatments result in a decrease in
albuminuria and the responses are mainly dependent on the lowering of
systemic blood pressure. In normotensive patients with incipient dia-
betic nephropathy, a lowering of mean blood pressure with CEI or CCB
is not found consistently while effects on albuminuria are difficult to
interpret. Short- and long-term therapy with CE! lowers or stabilizes
albuminuria. Short-term administration of CCB has at times been
associated with increases in albuminuria, but a comparison of CE! and
CCB over 12 months in the Melbourne Diabetic Nephropathy Study
(MDNS) has shown that both drugs stabilize albuminuria with no
significant differences in their effects. Serial analysis of urinary sodium
excretion in the MDNS shows that the hypotensive response to CE! in
incipient nephropathy is highly dependent on sodium intake, and that
sodium intake may modulate albuminuria during both CE! and CCB
therapy. In a subgroup of MDNS participants, examination of albumin
excretion rates before and after treatment suggests that the natural
history of evolution of albuminuria may have been ameliorated during
CEI and CCB therapy. In patients with type I! diabetes and albuminuria
in the incipient nephropathy range, the responses of blood pressure and
albuminuria to CEI and CCB have been similar and in genera! parallel
to those observed in younger patients with type I diabetes and incipient
nephropathy, Long-term studies are needed to determine whether a
decrease in albuminuria induced by CEI or CCB in patients with
incipient diabetic nephropathy delays or reduces the subsequent rate of
decline in glomerular filtration rate and renal structural changes.
Based on retrospective studies from the 1930s to the l960s it
has been frequently stated that diabetic nephropathy affects 30
to 35% of patients with type I diabetes [II, although recent
evidence suggests that its incidence is decreasing [2], The
clinical course of established diabetic nephropathy has also
improved recently. For instance, the live year survival rate of
© 1992 by the International Society of Nephrology
patients with persistent proteinuria has increased from less than
20% before 1970 to approximately 50% in the last 20 years [3].
Although improved glycemic control may have played a part, a
major reason for the apparent change in the natural history of
diabetic nephropathy is likely to be earlier and more effective
antihypertensive therapy [4—6]. In any given patient, it is not
easy to determine the relationship between diabetic nephrop-
athy and hypertension which theoretically could be cause-
effect, association or effect-cause, Longitudinal studies per-
formed in Denmark have shown that incipient diabetic
nephropathy generally precedes the onset of hypertension in
type I diabetic patients [7] and cross sectional studies have also
shown that a small rise in blood pressure is a feature of incipient
nephropathy [8, 9]. It may be possible to separate patients with
essential hypertension and microalbuminuria from patients with
incipient diabetic nephropathy and elevation of blood pressure
as part of the nephropathic syndrome, on the basis of the ratio
between the level of mean blood pressure and the degree of
microalbuminuria [101. However, it is not known if such a
distinction is reflected in the clinical course of the disorder.
The purpose of the present report is to compare and contrast
the effects of CE! and CCB in incipient diabetic nephropathy, to
determine if there is evidence for a specific effect of either
agent, and to assess if long-term therapy with these agents
delays progression to established diabetic nephropathy.
Diagnosis of incipient diabetic nephropathy
The diagnosis of incipient diabetic nephropathy is based on
the non-structural criterion of persistent microalbuminuria [9].
Although more than one study has shown that approximately
80% of type I diabetic patients with microalbuminuria progress
to established diabetic nephropathy after intervals of approxi-
mately 10 years [11—131, this high positive predictive value may
not necessarily apply outside the context of study populations.
For instance, non-diabetic renal disease was shown to occur in
over 20% of renal biopsies performed in patients with diabetes
and persistent proteinuria [14], and a similar percentage of
non-diabetic renal disease was documented in type II diabetic
patients without retinopathy [15]. In patients with type II
diabetes, even more caution needs to be exercised before
concluding that persistent microalbuminuria indicates incipient
diabetic nephropathy since microalbuminuria has been shown
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to occur in non-diabetic patients with macrovascular disease
[161 and hypertension [17]. Furthermore, early cardiac failure
and lower urinary tract disorders are common in the elderly and
may be difficult to distinguish from incipient nephropathy.
These considerations do not diminish the importance of docu-
menting increased albumin excretion in patients with type II
diabetes because it has been shown that microalbuminuria in
these patients is strongly related to subsequent cardiovascular
death [18, 19].
A recent comparison of structure-function relationships in
microalbuminuric patients has shown that significant glomeru-
lar mesangial expansion and basement membrane thickening
occur only when microalbuminuria is accompanied by a rise in
blood pressure or a fall in glomerular filtration rate [20]. These
findings imply that urinary albumin excretion rate alone may
not allow definitive conclusions to be made about the preven-
tion or progression of incipient nephropathy.
To demonstrate a specific effect of CE! or CCB on the course
of incipient diabetic nephropathy it would be necessary to
perform a controlled study in three treatment groups: placebo,
CE! and CCB. To allow for the annual increment of 20 to 50%
in albumin excretion rate and 3 to 4 mm Hg in blood pressure in
incipient nephropathy [21], and to document that any long-term
reduction in albuminuria is coupled to changes in glomerular
filtration rate, three very large groups of patients would need to
be studied for over five years. This assessment is based on the
results of previous work on the predictive power of microalbu-
minuria, which has shown that an interval of 5 to 14 years
may elapse before microalbuminuria converts to established
nephropathy [11—13, 221.
Effects of antihypertensive therapy in diabetic nephropathy
It is appropriate to consider the published evidence for the
effects of conventional antihypertensive agents in diabetic
nephropathy before focusing on the effects of CE! and CCB. !n
hypertensive patients with established diabetic nephropathy,
six years of treatment with beta adrenergic blockers, hydral-
azine, prazosin and frusemide to achieve a mean blood pressure
of approximately 110 mm Hg was shown to halve the rate of
decline of glomerular filtration rate and to practically arrest the
yearly increase in albuminuria [6]. !n a similar group of patients,
more aggressive antihypertensive therapy with beta adrenergic
blockers, methyl dopa, clonidine and diuretics maintained mean
blood pressure levels at approximately 100 mm Hg [23]. This
was associated with a reduction in albuminuria to less than half
of pre-treatment levels and a reduction in the rate of decline of
glomerular filtration rate from a range of 8 to 14 to approxi-
mately 3 ml/min/year during three years of treatment [24].
Subsequent studies using CE! in established diabetic nephrop-
athy have shown very similar effects on albuminuria and rate of
decline in renal function [251. These studies can be criticized
because of the lack of a concurrent control group, but the
weight of evidence nevertheless supports the use of aggressive
antihypertensive therapy in established diabetic nephropathy.
Approximately one third of patients with established diabetic
nephropathy and approximately two thirds of patients with
incipient nephropathy can be classified as normotensive [26].
The effects of antihypertensive therapy have recently been
studied in normotensive patients with either established or
incipient diabetic nephropathy. The impetus to assess the
effects of antihypertensive therapy in normotensive patients
was initially derived from studies in rats with either subtotal
nephrectomy [27] or streptozotocin diabetes [28]. It was postu-
lated that raised intraglomerular pressure may contribute to the
progression of various renal disorders including diabetic
nephropathy [29]. Further studies in streptozotocin diabetic
rats showed that CE! may arrest the progress of experimental
diabetic nephropathy, possibly through a specific intrarenal
action independent of systemic blood pressure [28]. This evi-
dence suggested that CE! may reverse the action of angiotensin
!! on the efferent glomerular arteriole and thereby lower intra-
glomerular pressure. However, it remains to be determined if
these concepts can be applied to diabetic nephropathy in man,
since no existing model of experimental diabetic nephropathy is
associated with progressive renal impairment.
Short-term effects of CE! and CCB in incipient diabetic
nephropathy
It is possible that any specific effects of long-term CEI or
CCB on the clinical course of incipient diabetic nephropathy
may be reflected in differences in their acute effects on renal
hemodynamics. Experimental studies have shown that CE!
lower intraglomerular pressure by selectively relaxing the effer-
ent glomerular arteriole [29]. However, not all groups agree that
angiotensin !! acts only on the efferent arteriole with several
studies detecting an effect of angiotensin I! (Ang II) on the
afferent arteriole [30]. Furthermore, CEI may act by mecha-
nisms independent of intraglomerular pressure. Recent experi-
mental studies have suggested that the effects of CE! may be
mediated by actions on renal growth [31] or on glomerular
barrier function [32]. The effects on glomerular barrier function
have recently been reported in a study of CE! in diabetic
patients with established nephropathy [33].
By contrast, CCB may act predominantly by relaxing the
afferent glomerular arteriole, and it has been suggested that this
may increase intraglomerular pressure [34]. However, there is a
lack of agreement on the effects of CCB in experimental models
of renal disease. It has been suggested by another group that the
effects of Ang !I on the efferent arteriole are calcium dependent
and can be inhibited by calcium antagonists [35]. Furthermore,
nifedipine has been reported to increase intrarenal renin levels
[36]. Therefore, there is no agreement at this stage as to
whether CCB act predominantly on the afferent or efferent
arteriole. Furthermore, one cannot exclude the possibility that
in certain contexts CCB and CE! may act in a very similar
manner within the kidney. !n uninephrectomized STZ diabetic
rats, CCB failed to lower proteinuria whereas CEI, given in
equihypotensive doses, markedly decreased proteinuria [37].
However, although differences in the intrarenal actions of CE!
and CCB may be relevant to man under certain circumstances,
such as renovascular hypertension [38, 39], no persuasive
evidence exists to suggest that they override the common
actions of CEI and CCB in lowering systemic blood pressure.
Direct comparisons of CEI and CCB in diabetic patients have
not revealed major differences in their actions on renal hemo-
dynamics (Table 1). One study has shown that CCB elevate
glomerular filtration rate in patients with incipient nephropathy,
whereas CE! do not influence glomerular filtration rate acutely
[40]. CE! but not CCB reduce filtration fraction, especially in
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Table 1. Converting enzyme inhibition versus calcium channel blockade in diabetes
Mean BP
mm Hg AER gImin GFR mi/mm FF
Study Patient Drug (patient (treatment (treatment (treatment (treatment
[reference] characteristics Duration numbers) effect) effect, %) effect, %) effect)
Short-term
O'Brien Type I 2 weeks Nifedipine (18) 92 (NS) 6.2 (NS) 124 0.25 (NS)
1989 [41] normal
AER
normotensive
Enalapril (18) 93 (—6) 5.9 (NS) 125 (NS) 0.26 (—0.02)
Bib Type I 3 hours Nifedipine (8) 98 (—8) — 122 (+6) 0.23 (NS)
1990 [40] incipient
normotensive
Captopril (7) 99 (—6) — 140 (NS) 0.26 (—0,02)
Post exercise
increment
Romanelli Type I 3 hours Nifedipine (25) 105 (—15) (—40%) —
1989 [471 incipient
normotensive
Captopril (25) 105 (NS) (_80%)a
Mimran Type I 6 weeks Nifedipine (7) 99 (—5) 86 (+42%) —
1988 [51] incipient
normotensive
Captopril (8) 99 (—6) 34 (4l%)a
Baba Type II 4 weeks Nicardipine (7) (—19) (—43%) (NS)
1989 [52] incipient
hypertensive
cross over Enalapril (7) 122
(—15)
33
(—32%)
93
(NS)
Stornello Type II 4 weeks Nicardipine (12) (—16) (—61%) (NS)
1989 [53] established
hypertensive
cross over Captopril (12) 131
(—14)
833
(—48%)
113
(NS)
Bakris Type II 4 weeks Diltiazem (8) (—24) (—32%) (NS)
1990 [54] established
hypertensive
cross over Lisinopril (8) 118
(—21)
2750
(—37%)
83
(NS)
Holdaas Type I 3 weeks Nifedipine (12) (—14) (NS) (NS)
1990 [551 established
hypertensive
cross over Lisinopril (12) 110
(—8)
1343
(_35%)a
—
(NS)
Long-term
MDNS Type I & II 52 weeks Nifedipine (13) 99 (—5, NS) 31 (NS) 120 (NS)
1991 [60] incipient
normotensive
Type I & II
incipient
hypertensive
52 weeks
Perindopril (17)
Nifedipine (10)
Perindopril (3)
99 (—3, NS)
119 (—12)
119 (—12)
34 (NS)
69 (—30)
32 (—28)
151 (NS)
150 (NS)
103 (NS)
Chan Type II 24 weeks Nifedipine (II) — 64 (—75) —
1991 [611 incipient
hypertensive
Enalapril (12) — 50 (—64) —
CEI vs. CCBa p < 0.05,
Abbreviations are: BP, blood pressure; AER, albumin excretion rate; GFR, glomerular filtration rate; FF, filtration fraction; NS, not significant;
incipient, AER 20 to 200 /,sg/min; established, AER > 200 g/min.
hyperfiltering patients [411. Similar effects of CE! on filtration
fraction have also been observed in type I diabetic patients with
normoalbuminuria [42] and with incipient nephropathy [43],
providing indirect evidence of a reduction in intraglomerular
pressure by CEI. However, not all human studies have docu-
mented decreases in filtration fraction with CE! [44—461. Fur-
ther evidence of subtle differences in the intrarenal effects of
CE! and CCB has been provided in a study of their acute effects
on post-exercise albuminuria [47]. This has shown that CEI
cause a greater reduction in post-exercise albuminuria, despite
a greater reduction in systemic blood pressure by CCB. Several
other groups have suggested that CE! can act independently of
effects on systemic blood pressure [45, 481. Such effects on
albuminuria independent of blood pressure have not been
reported with CCB although this class of antihypertensive
agents has not been studied as extensively as CE!.
Effects of CE! and CCB in normotensive patients with incipient
diabetic nephropathy
In untreated normotensive patients with established diabetic
nephropathy there is evidence that blood pressure and albumin-
uria rise over 52 weeks and that CE! can prevent these changes
[491. Studies in normotensive patients with incipient diabetic
nephropathy are more difficult to interpret. Studies with CE!
extending over 12 to 48 months have shown that CE! decrease
urinary albumin excretion when used as monotherapy initially
and later combined with a diuretic [50] or prevent the rise in
albuminuria observed in concurrent control groups [44]. In the
latter studies [44, 50], the effects of CE! on albuminuria were
not related to changes in systemic blood pressure, although
such a relationship was demonstrable in the control group in
one study [44]. Two short-term comparisons of CEI and CCB
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have been performed in patients with incipient diabetic
nephropathy (Table 1). One has shown that captopril lowered
albumin excretion rate in eight normotensive patients with
incipient nephropathy after six weeks, whereas nifedipine
raised albumin excretion rate in seven patients, despite a small
but equal decrease in mean blood pressure of approximately 5
mm Hg with either agent [511. By contrast, a crossover com-
parison of CE! and CCB in seven hypertensive patients with
incipient diabetic nephropathy has shown that both enalapril
and nicardipine lower blood pressure and albumin excretion
rates to a similar degree over four weeks [521.
Short-term comparisons of CE! and CCB in established
diabetic nephropathy
Short-term comparisons of CEI and CCB have also been
performed in hypertensive patients with established diabetic
nephropathy (Table 1). Two studies have shown a reduction in
albuminuria and systemic blood pressure with both forms of
therapy [53, 541, whereas the other study has shown that
albuminuria is reduced by lisinopril but not by nifedipine used
in doses which reduce systemic blood pressure to a similar or
greater degree [55]. However, it must be emphasized that there
is no evidence to suggest that two point measurements of
albuminuria extending over three to six weeks can predict the
outcome of long-term therapy with CEI or CCB, as is evident
from an examination of the variability of albumin excretion in
individual patients with time [56—58].
Long-term effects of CEI and CCB in incipient nephropathy
Previous reports evaluating the effects of antihypertensive
therapy in incipient diabetic nephropathy over at least a 12
month period include studies using the beta blocker, metoprolol
[59], or CEI with enalapril [44]. These studies noted reduction
in albuminuria with these antihypertensive agents. Two recent
long-term comparisons of the effects of CE! and CCB in
incipient diabetic nephropathy have been performed by the
Melbourne Diabetic Nephropathy Study (MDNS) [60l and by
Chan et a! [61]. The MDNS was a randomized study of
hypertensive [N = 13) and normotensive (N = 30) type I and
type II diabetic patients with persistent microalbuminuria (al-
bumin excretion rate 20 to 200 g/min). Participants were
randomly assigned to treatment with perindopril (N = 20) or
nifedipine (N = 23) in doses aiming for equivalent hypotensive
efficacy. The effects on blood pressure, albuminuria and gb-
merular filtration rate were analyzed.
In hypertensive patients, defined according to WHO criteria
as systolic blood pressure l60 mm Hg and diastolic blood
pressure 95 mm Hg after five minutes in the supine position,
the aim of treatment was to decrease blood pressure to <160/90
mm Hg and in normotensive patients the aim was to decrease
diastolic blood pressure by more than 5 mm Hg. The study was
performed in three centers but all urinary albumin assays were
performed in a central reference laboratory. The comparison of
mean blood pressure and albumin excretion rates in the penn-
dopril and nifedipine treated groups was performed by the
method of summary measures utilizing the mean of each
parameter (mean blood pressure or albumin excretion rate)
before treatment and on treatment (at 1, 3, 6, 9 and 12 months).
The effect of ceasing treatment was also studied by comparing
the mean for blood pressure and albuminuria for the three
months before cessation of therapy to the three months after
cessation of therapy.
No significant differences were observed in the blood pres-
sure or albuminuria response of patients treated with penn-
dopril or nifedipine, whether hypertensive or normotensive
(Fig. 1, Table 1). In 13 hypertensive patients, antihypertensive
therapy was associated with a decrease in mean blood pressure
of 12 mm Hg and a decrease of albuminunia of 30%, but no
significant differences were observed between perindopril and
nifedipine treated patients. In normotensive patients, mean
blood pressure decreased by 4 mm Hg (P < 0.05) but there was
no significant decrease in albumin excretion rate with either
treatment over 12 months. In particular, there was no signifi-
cant difference in albuminuria between perindopril and nife-
dipine treated patients. After stopping therapy in the 30 nor-
motensive patients, mean blood pressure rose significantly after
one month, with the increase in mean blood pressure being
more marked in the perindopril treated group than in the
nifedipine treated group (P < 0.002). It is possible that chronic
CE! leads to Ang II suppression with resultant compensatory
vasoconstrictor mechanisms to maintain blood pressure. Ces-
sation of CE! would restore Ang II levels and result in a
rebound in blood pressure levels. No such effects on Ang II
would occur with CCB. Albuminuria increased significantly
with no difference between the two treatment groups one month
after stopping antihypertensive therapy.
There was no significant difference in albumin excretion rates
between type I and type H diabetic patients before or during the
12 month study period, with geometric means for baseline and
on treatment albumin excretion rates being 37.3 and 25.2
g/min in type I and 37.2 and 32.7 g/min in type II patients,
respectively. Geometric means for albumin excretion rates on
and off therapy were 31.1 and 76.4 g/min, respectively, for
type II patients (P < 0.05) and 23.8 and 27,8 g/min in type I
patients (NS), respectively. The reasons for these differences in
response of albumin excretion rates to cessation of antihyper-
tensive therapy in type I and type II diabetic patients are not
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Fig. 1. Albuminuria results are shown for all 43 patients in the Mel-
bourne Diabetic Nephropathy Study as geometric means and tolerance
factors. Antihypertensive therapy was administered from 0 to 12
months, using perindopnil (solid symbols) or nifedipine (open symbols).
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clear. No significant differences in glycemic control were ob-
served throughout the study and the increments in mean blood
pressure following cessation of antihypertensive therapy were
similar in type I and type II diabetic patients. The rises in mean
blood pressure after cessation of treatment were similar in type
I and type II diabetic patients (type I, 15 4 vs. type II, 21
3 mm Hg, P = 0.22). No patients developed overt evidence of
cardiac failure. It is possible that this difference in response of
albumin excretion rates to cessation of treatment reflects dif-
ferent causes of microalbuminuria in the two types of diabetes.
During 12 months of antihypertensive therapy, no significant
differences in glomerular filtration rate were observed overall or
between CE! and CCB treated patients. However, in twenty
hyperfiltering patients (>135 ml/min/l.73 m2), both treatments
resulted in a fall in glomerular filtration rate 1601. Whether this
effect will ultimately modify rates of nephron loss will require
further long-term study.
The conclusions of the MDNS were that blood pressure is an
important determinant of albumin excretion in incipient diabetic
nephropathy. Both perindoprit and nifedipine prevent increases
in albumin excretion in normotensive patients and decrease
albumin excretion rates in hypertensive patients [60]. Similar
results with respect to hypertensive microalbuminuric type II
diabetic patients have been observed in a recent preliminary
report [61].
The rebound of albuminuria after cessation of therapy may
indicate that there has been no significant change in the natural
history of progression of albuminuria in these patients. To study
this, we have analyzed the evolution of albuminuria in a
subgroup of participants in which we had at least three years of
data on albumin excretion rates before commencement of
antihypertensive therapy (Fig. 2). This was performed to deter-
mine if the levels of albumin excretion observed after cessation
of antihypertensive therapy approximate the levels expected
from the percentage increments in albumin excretion rates in
previous years in the same subjects. In 10 of the 43 patients,
serial albuminuria data were available for a minimum of 36
Fig. 2. Serial albuminuria data (left y axis,
logarithmic scale) for 10 patients from the
Melbourne Diabetic Nephropathy Study for
the 36 months before treatment (—36 to 0
months), 12 months on treatment (0 to 12
months, hatched zone) and 12 months after
stopping treatment (12 to 24 months) are
shown as geometric means and tolerance
factors (solid line). Serial mean blood
pressure data (right y axis) are shown as mean
SEM (grey line). Symbols are: (---) mean
blood pressure; (—) albuminuria.
months prior to the start of the study. In these patients, there
was a progressive rise in albuminuria over the 42 month period
before treatment (r 0.89, P = 0.003) corresponding to a mean
increase of 46% per year (Fig. 2). During 12 months of antihy-
pertensive treatment there was a reversal of this trend. After
cessation of antihypertensive therapy albuminuria increased at
a rate which was not significantly different from pre-treatment
levels. These results suggest that antihypertensive therapy has
altered the rate of evolution of albuminuria, and raise the
possibility that progression to established diabetic nephropathy
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Fig. 3. The relationship between change in albuminuria during therapy
(pre- versus mean of 1-12 month results) and urinary sodium/creatinine
ratio on treatment is shown for perindopril (solid symbols) and nife-
dipine treated patients (open symbols). For the group as a whole, the
correlation coefficient was r = 0.39, P 0.009 (perindopril, r = 0.39, P
= 0.09; nifedipine, r = 0.40, P = 0.06).
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Fig. 4. The relationship between change in
mean blood pressure (MBP) during /2 months
0 of therapy and urinary sodiumicreatinine ratio0 on treatment is shown for perindopril (solid
symbols, r = 0.57, P = 0.008, N = 20) and
for nifedipine treated patients (open symbols,
= 0.02, P = 0.94, N = 23). In perindopril
treated patients, the regression line was y =
30 40 l.04x — 21.6, where y = change in mean
blood pressure and x = urinary
sodium/creatinine ratio.
may have been delayed. Furthermore, changes in mean blood
pressure paralleled the changes in urinary albumin excretion.
Influence of sodium status on the actions of CEI and CCB
The MDNS [60] has shown in 43 patients with incipient
diabetic nephropathy that the change in albuminuria during 12
months of antihypertensive therapy with either perindopril or
nifedipine correlated with the change in mean blood pressure (r
= 0.37, P = 0.016). The correlation coefficients for the relation-
ship between changes in albuminuria and mean blood pressure
were 0.38 (P = 0.09) and 0.37 (P = 0.09) for perindopril and
nifedipine treated patients, respectively. We have now ana-
lyzed the relationship between the change in albuminuria during
12 months of antihypertensive therapy with the mean urinary
sodium excretion during the same interval in each patient. This
has shown that the change in albuminuria, expressed as the
difference in log transformed albumin excretion rate, is also
significantly related to the urinary sodium/creatinine ratio (r =
0.39, P = 0.009; Fig. 3). It has been previously shown that the
acute natriuretic effects of CE! and CCB are fully expressed
within one week after initiation of therapy [62, 63], so that the
present analysis of urinary sodium excretion based on results at
1, 3, 6, 9 and 12 months of therapy is likely to reflect dietary
sodium status rather that drug effect. This was confirmed in the
present study which showed no change in the urinary sodium!
creatinine ratio either before or during antihypertensive ther-
apy. These findings suggest that in patients with incipient
nephropathy a substantial component of the variability in
response of albuminuria to antihypertensive therapy can be
explained by variations in not only mean blood pressure but
also sodium intake.
A further analysis was performed of the relationship between
sodium status and the change in mean blood pressure during 12
months of antihypertensive therapy. For the whole study
group, no significant relationship was found (r = 0.18, P =
0.26). In nifedipine treated patients, there was also no signifi-
cant relationship (r 0.016, P = 0.94, N = 23, Fig. 4).
However, in perindopril treated patients, there was a highly
significant relationship between the change in mean blood
pressure and urinary sodium excretion (r = 0.57, P = 0.008, N
= 20, Fig. 4). These results are consistent with the short-term
data obtained in non-diabetic patients with intrinsic renal dis-
ease [64, 65], and emphasize the potential modulating role of
sodium intake on albuminuria during antihypertensive therapy
and the specific relationship between sodium intake and anti-
hypertensive efficacy in CEL treated patients.
The influence of sodium intake on the effectiveness of CE!
has been documented previously in experimental and human
studies. In rats with streptozotocin diabetes, it has been shown
that a high salt intake impairs the blood pressure lowering
action of CEI and also neutralizes the antiproteinuric effect of
CE! [66]. Studies of lisinopril over two weeks in normotensive
non-diabetic patients with intrinsic glomerular disease, have
shown that proteinuria is highly dependent on sodium intake
during CE! [651. Thus, proteinuria of approximately 6 g/24 hr
during methyl dopa therapy was halved during lisinopril therapy
with sodium restriction of 50 mmol/24 hr. However, the antipro-
teinuric effect of lisinopril practically disappeared after chang-
ing to a high salt intake of 200 mmol/24 hr. Such an effect of
sodium intake has not been previously described in studies with
CCB. The present evidence suggests that even though mean
sodium intake is unchanged for the study group as a whole,
variations in sodium intake between different patients and also
in individual patients from day to day, may contribute to the
effects of both CE! and CCB on blood pressure and albumin-
uria.
Conclusions
It is concluded that both CEI and CCB have similar effects on
renal functional parameters in incipient nephropathy. In medi-
um-term studies, neither CE! or CCB have shown a significant
effect on glomerular filtration rate, although CE! may acutely
reduce filtration fraction, particularly in hyperfiltering patients.
Most, hut not all, studies have shown that CE! and CCB reduce
albuminuria in incipient nephropathy. In hypertensive patients,
this effect is linked to a reduction in systemic blood pressure. In
normotensive patients, CEI and CCB reduce albuminuria to a
lesser extent and not all studies have shown a fall in systemic
blood pressure. Furthermore, changes in albuminuria during
CE! and CCB are dependent on dietary sodium restriction.
Thus, predictions on the course of incipient nephropathy based
on albumin excretion rates alone may not be valid. Despite
these reservations, longitudinal analysis of albumin excretion
rates before and after antihypertensive therapy does suggest
that the natural history of evolution of albuminuria has been
modified by CE! and CCB.
Long-term placebo-controlled studies are needed to deter-
mine if the effects induced by CEI or CCB on albuminuria are
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ultimately coupled to rates of decline in renal function and renal
structural changes.
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